David G. Warnock - Concepedia

Author

David G. Warnock

University of Alabama at Birmingham ORCID

Also Known As

Adeera Levin, Balcells, Claudio Ronco, D G Warnock, D WARNOCK, D. G. WARNOCK, D. G. Warnock, D. Warnock, D.G. Warnock, DAVID G. WARNOCK

330

Publications

22.7K

Citations

H-Index

164

Concepts

All Affiliations

University of Alabama at Birmingham Emory University University College London University of Würzburg Hospital de São João

About

David G. Warnock is an author at University of Alabama at Birmingham specializing in medicine, nephrology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	65	4.4K
2	Natural Sciences	12	12	680
3	Public Health	7	7	840
4	Engineering	3	3	161
5	Health Sciences	1	1	28

David G. Warnock

134

Publications

18.9K

Citations

H-Index

Page 1

	Year	Citations
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury Ravindra L. Mehta, John A. Kellum, Sudhir V. Shah, Critical Care	2007	7K
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes Pablo E. Pérgola, Philip Raskin, Robert D. Toto, New England Journal of Medicine	2011	868
Agalsidase-Beta Therapy for Advanced Fabry Disease Maryam Banikazemi, Jan Bultas, Stephen Waldek, Annals of Internal Medicine	2007	564
Acute Kidney Injury and Mortality in Hospitalized Patients Henry E. Wang, Paul Muntner, Glenn M. Chertow, American Journal of Nephrology	2012	529
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry William R. Wilcox, João Paulo Oliveira, Robert J. Hopkin, Molecular Genetics and Metabolism Fabry DiseaseMendelian DisorderPathologyGynecologyMedicine	2007	526
Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States Rajiv Agarwal, Allen R. Nissenson, Daniel Batlle, The American Journal of Medicine HypertensionUrologyHemodialysisCardiovascular DiseaseHealth Policy	2003	475
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy Raphael Schiffmann, David G. Warnock, Maryam Banikazemi, Nephrology Dialysis Transplantation	2009	361
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease Dominique P. Germain, Joel Charrow, Robert J. Desnick, Journal of Medical Genetics	2015	355
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure Raimund Hirschberg, Joel D. Kopple, Pamela Lipsett, Kidney International	1999	304
Angiotensin II Directly Stimulates ENaC Activity in the Cortical Collecting Duct via AT1 Receptors János Peti‐Peterdi, David G. Warnock, P. Darwin Bell Journal of the American Society of Nephrology	2002	297

Page 1